Research programme: peripherally acting cannabinoid receptor CB1 agonists - Corbus Pharmaceuticals
Alternative Names: JD-2000 series; JD-2114; JD-5000 series; JD-5006; JD-6000 seriesLatest Information Update: 11 Mar 2022
At a glance
- Originator Jenrin Discovery
- Developer Corbus Pharmaceuticals
- Class Antifibrotics; Antihyperglycaemics; Antihyperlipidaemics; Hepatoprotectants; Obesity therapies; Small molecules
- Mechanism of Action Cannabinoid 1 receptor inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity
- No development reported Atherosclerosis; Dyslipidaemias; Non-alcoholic fatty liver disease; Type 2 diabetes mellitus